Scalper1 News
The FDA approved Amgen’s (AMGN) cholesterol drug Repatha late Thursday, giving it a similar label to a recently approved rival from Regeneron (REGN) and Sanofi (SNY), but a slightly lower price. The agency said it had cleared Repatha, one of the new PCSK9 inhibitor class of drugs, for patients with heterozygous familial hypercholesterolemia (HeFH), homozygous familial hypercholesterolemia (HoFH), and patients with heart disease who need more Scalper1 News
Scalper1 News